middle.news
Botanix’s Sofdra Sales Surge Fuels $40M Capital Raise and $30M Debt Facility
9:12am on Monday 28th of July, 2025 AEST
•
Healthcare
Read Story
Botanix’s Sofdra Sales Surge Fuels $40M Capital Raise and $30M Debt Facility
9:12am on Monday 28th of July, 2025 AEST
Key Points
Sofdra net revenue increased over sixfold from Q3 to Q4 2025
Unique prescribers more than doubled, prescriptions shipped grew 324%
Raised $40 million via institutional placement and secured $30 million debt facility
Cash position strong at $64.9 million supporting sales force expansion
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Botanix Pharmaceuticals (ASX:BOT)
OPEN ARTICLE